Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
The recent market correction and market's overreaction to the supposedly softer Wegovy sales have triggered NVO's discounted entry points. With Ozempic/Wegovy no longer in shortage and manufacturing capacity continuing to ramp up, it is unsurprising that the management has raised their FY2024 guidance. NVO continues to report robust GLP-1, obesity, and diabetic therapy market shares in the North American and International regions as well.
Novo Nordisk Pharmatech unit to build $220 mln plant in Denmark
Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic diseases, the company said on Friday.
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Novo Nordisk's recent earnings numbers came in slightly lower than expectations. The company also reduced its forecast for earnings growth this year.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Stable Blue-Chip Stocks to Buy for the Market Storm
The volatility that has rocked markets since the beginning of July might not be over just yet. August has proven to be extremely rocky.
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
Novo Nordisk has had a somewhat rough summer. Two different interactions with regulators didn't go its way.
Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
One of Novo Nordisk's medicines could be helpful for treating Alzheimer's disease. A lot of questions need answering before it'll make any new revenue.
